Vivek Subbiah

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 145

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

NPJ precision oncology

Nature medicine

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Vivek Subbiah, Mohamed A Gouda, Bettina Ryll, Howard A Burris, Razelle Kurzrock
The evolving landscape of tissue-agnostic therapies in precision oncology. CA: a cancer journal for clinicians 74 (5) (2024)
Deepak Bhamidipati, Andrew J Pellatt, Vivek Subbiah
Targeting All BRAF Alterations: The (Re)-Search Continues. JCO precision oncology 8 (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer research communications 4 (2) (2024)
Kristian Thorlund, Stephen Duffield, Sanjay Popat, Sreeram V Ramagopalan, Alind Gupta, Grace G Hsu, Paul Arora, Vivek Subbiah
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers. Journal of comparative effectiveness research 13 (3) (2024)
Deepak Bhamidipati, Andrew J Pellatt, Vivek Subbiah
Targeting All BRAF Alterations: The (Re)-Search Continues. JCO precision oncology 8 (2024)
Andrew J Pellatt, Deepak Bhamidipati, Vivek Subbiah
Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer. JCO oncology practice (2024)
Kristian Thorlund, Stephen Duffield, Sanjay Popat, Sreeram V Ramagopalan, Alind Gupta, Grace G Hsu, Paul Arora, Vivek Subbiah
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers. Journal of comparative effectiveness research 13 (3) (2024)
Lori J Wirth, Marcia S Brose, Vivek Subbiah, Francis Worden, Benjamin J Solomon, Bruce Robinson, Julien Hadoux, Pascale Tomasini, Daniela Weiler, Barbara Deschler-Baier, Daniel Shao-Weng Tan, Patricia Maeda, Yan Lin, Ravinder Singh, Theresa Bayt, Alexander E Drilon, Philippe Alexandre Cassier
Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Kristian Thorlund, Stephen Duffield, Sanjay Popat, Sreeram V Ramagopalan, Alind Gupta, Grace G Hsu, Paul Arora, Vivek Subbiah
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers. Journal of comparative effectiveness research 13 (3) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Sarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D Karp, Vivek Subbiah, David Hong, Siqing Fu, Aung Naing, Jordi Rodon, Milind Javle, Jaffer A Ajani, Kanwal P S Raghav, Neeta Somaiah, Gordon B Mills, Apostolia-Maria Tsimberidou, Xiaofeng Zheng, Ken Chen, Funda Meric-Bernstam
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ precision oncology 8 (1) (2024)
Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel Karp, Vivek Subbiah, Jordi Rodon Ahnert, Sarina A Piha-Paul, John Wright, Senait N Fessahaye, Fengying Ouyang, Bulent Yilmaz, Funda Meric-Bernstam, Aung Naing
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer medicine 13 (3) (2024)
Deepak Bhamidipati, Andrew J Pellatt, Vivek Subbiah
Targeting All BRAF Alterations: The (Re)-Search Continues. JCO precision oncology 8 (2024)
Vivek Subbiah, Denis Horgan, Ishwaria M Subbiah
A Vision for Democratizing Next-Generation Oncology Clinical Trials. Cancer discovery 14 (4) (2024)
Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel Karp, Vivek Subbiah, Jordi Rodon Ahnert, Sarina A Piha-Paul, John Wright, Senait N Fessahaye, Fengying Ouyang, Bulent Yilmaz, Funda Meric-Bernstam, Aung Naing
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer medicine 13 (3) (2024)
Vivek Subbiah, Mohamed A Gouda, Bettina Ryll, Howard A Burris, Razelle Kurzrock
The evolving landscape of tissue-agnostic therapies in precision oncology. CA: a cancer journal for clinicians (2024)
Blessie Elizabeth Nelson, Vivek Subbiah
Predicting the Abscopal Phenomenon-Reply. Molecular cancer therapeutics 23 (2) (2024)
Vivek Subbiah
Fragmentation in medicine harms patients and hinders research. Nature medicine (2024)
Kristian Thorlund, Stephen Duffield, Sanjay Popat, Sreeram V Ramagopalan, Alind Gupta, Grace G Hsu, Paul Arora, Vivek Subbiah
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers. Journal of comparative effectiveness research 13 (3) (2024)
Kristian Thorlund, Stephen Duffield, Sanjay Popat, Sreeram V Ramagopalan, Alind Gupta, Grace G Hsu, Paul Arora, Vivek Subbiah
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers. Journal of comparative effectiveness research (2024)
Deepak Bhamidipati, Andrew J Pellatt, Vivek Subbiah
Targeting All BRAF Alterations: The (Re)-Search Continues. JCO precision oncology 8 (2024)
Deepak Bhamidipati, Andrew J Pellatt, Vivek Subbiah
Targeting All BRAF Alterations: The (Re)-Search Continues. JCO precision oncology 8 (2024)
Sarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D Karp, Vivek Subbiah, David Hong, Siqing Fu, Aung Naing, Jordi Rodon, Milind Javle, Jaffer A Ajani, Kanwal P S Raghav, Neeta Somaiah, Gordon B Mills, Apostolia-Maria Tsimberidou, Xiaofeng Zheng, Ken Chen, Funda Meric-Bernstam
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Sarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D Karp, Vivek Subbiah, David Hong, Siqing Fu, Aung Naing, Jordi Rodon, Milind Javle, Jaffer A Ajani, Kanwal P S Raghav, Neeta Somaiah, Gordon B Mills, Apostolia-Maria Tsimberidou, Xiaofeng Zheng, Ken Chen, Funda Meric-Bernstam
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Blessie Elizabeth Nelson, Vivek Subbiah
Predicting the Abscopal Phenomenon-Reply. Molecular cancer therapeutics 23 (2) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Denis Horgan, Ishwaria M Subbiah
A Vision for Democratizing Next-Generation Oncology Clinical Trials. Cancer discovery 14 (4) (2024)
Kristian Thorlund, Stephen Duffield, Sanjay Popat, Sreeram V Ramagopalan, Alind Gupta, Grace G Hsu, Paul Arora, Vivek Subbiah
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers. Journal of comparative effectiveness research 13 (3) (2024)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer research communications 4 (2) (2024)
Lori J Wirth, Marcia S Brose, Vivek Subbiah, Francis Worden, Benjamin J Solomon, Bruce Robinson, Julien Hadoux, Pascale Tomasini, Daniela Weiler, Barbara Deschler-Baier, Daniel Shao-Weng Tan, Patricia Maeda, Yan Lin, Ravinder Singh, Theresa Bayt, Alexander E Drilon, Philippe Alexandre Cassier
Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Babar Bashir, Judy S Wang, Gerald S Falchook, Elisa Fontana, Hendrick-Tobias Arkenau, Louise Carter, Rachel Galot, Bristi Basu, Alastair P Greystoke, Vivek Subbiah, Debra L Richardson, Hanna Orr, Gavin Bennett, Rajiv Sharma, Hongmei Xu, Paola Paganoni, Cong Xu, Carly Campbell, Meredith A McKean
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Roberto Carmagnani Pestana, Justin Tyler Moyers, Jason Roszik, Shiraj Sen, David S Hong, Aung Naing, Cynthia E Herzog, Siqing Fu, Sarina A Piha-Paul, Jordi Rodon Ahnert, Timothy Anthony Yap, Daniel D Karp, Apostolia-Maria Tsimberidou, Shubham Pant, Maria Alejandra Zarzour, Ravin Ratan, Vinod Ravi, Robert S Benjamin, Alexander J F Lazar, Wei-Lien Wang, Najat C Daw, Jonathan D Gill, Douglas J Harrison, Valerae O Lewis, Christina Lynn Roland, Shreyaskumar R Patel, Jonathan A Livingston, Neeta Somaiah, Joseph A Ludwig, Anthony P Conley, Nelson Hammerschlak, Richard G Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Vivek Subbiah, Razelle Kurzrock
Reply to S. Sorscher. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Vivek Subbiah, Sant P Chawla, Anthony P Conley, Breelyn A Wilky, Anthony W Tolcher, Nehal J Lakhani, David Berz, Vasily Andrianov, William Crago, Monica Holcomb, Abrahim Hussain, Carson Veldstra, James Kalabus, Brianne O'Neill, Lane Senne, Emily Rowell, Analeah B Heidt, Katelyn M Willis, Brendan P Eckelman
Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Mohamed A Gouda, Lars Buschhorn, Andreas Schneeweiß, Adam Wahida, Vivek Subbiah
N-of-1 Trials in Cancer Drug Development. Cancer discovery (2023)
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B Barry Toure, Songping Zhao, Roberto Valverde, Patrick J O'Hearn, Demetri T Moustakas, Heike Schonherr, Nastaran Gerami-Moayed, Alexander M Taylor, Brandi M Hudson, Damian J Houde, Debjani Pal, Lindsey Foster, Hakan Gunaydin, Pelin Ayaz, Dina A Sharon, Lipika Goyal, Alison M Schram, Suneel D Kamath, Cori Ann Sherwin, Oleg Schmidt-Kittler, Kai Yu Jen, Fabien Ricard, Beni B Wolf, David E Shaw, Donald A Bergstrom, James Watters, Jessica B Casaletto
RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. Cancer discovery (2023)
Timothy Anthony Yap, Naval G Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric-Bernstam, Hagop M Kantarjian, Farhad Ravandi, Meghan E Collins, Maria Emilia Di Francesco, Ecaterina E Dumbrava, Siqing Fu, Sisi Gao, Jason P Gay, Sonal Gera, Jing Han, David S Hong, Elias J Jabbour, Zhenlin Ju, Daniel D Karp, Alessia Lodi, Jennifer R Molina, Natalia Baran, Aung Naing, Maro Ohanian, Shubham Pant, Naveen Pemmaraju, Prithviraj Bose, Sarina A Piha-Paul, Jordi Rodon, Carolina Salguero, Koiji Sasaki, Anand K Singh, Vivek Subbiah, Apostolia M Tsimberidou, Quanyun A Xu, Musa Ylimaz, Qi Zhang, Yuan Li, Christopher A Bristow, Meenakshi B Bhattacharjee, Stefano Tiziani, Timothy P Heffernan, Christopher P Vellano, Philip Jones, Cobi J Heijnen, Annemieke Kavelaars, Joseph R Marszalek, Marina Y Konopleva
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nature medicine 29 (1) (2023)
Vivek Subbiah, Howard A Burris, Razelle Kurzrock
Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer (2023)
Vivek Subbiah, Razelle Kurzrock
Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis . Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Vivek Subbiah
The next generation of evidence-based medicine. Nature medicine (2023)
Ryan A Denu, Justin Tyler Moyers, Mohamed A Gouda, Anthony P Conley, Alexander J F Lazar, Vivek Subbiah
The landscape of alterations from 1407 ultra-rare sarcomas from the AACR GENIE database: Clinical implications. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Timothy Anthony Yap, Naval G Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric-Bernstam, Hagop M Kantarjian, Farhad Ravandi, Meghan E Collins, Maria Emilia Di Francesco, Ecaterina E Dumbrava, Siqing Fu, Sisi Gao, Jason P Gay, Sonal Gera, Jing Han, David S Hong, Elias J Jabbour, Zhenlin Ju, Daniel D Karp, Alessia Lodi, Jennifer R Molina, Natalia Baran, Aung Naing, Maro Ohanian, Shubham Pant, Naveen Pemmaraju, Prithviraj Bose, Sarina A Piha-Paul, Jordi Rodon, Carolina Salguero, Koiji Sasaki, Anand K Singh, Vivek Subbiah, Apostolia M Tsimberidou, Quanyun A Xu, Musa Ylimaz, Qi Zhang, Yuan Li, Christopher A Bristow, Meenakshi B Bhattacharjee, Stefano Tiziani, Timothy P Heffernan, Christopher P Vellano, Philip Jones, Cobi J Heijnen, Annemieke Kavelaars, Joseph R Marszalek, Marina Y Konopleva
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nature medicine (2023)
Pashtoon Murtaza Kasi, Jessica K Lee, Lincoln W Pasquina, Brennan Decker, Pierre Vanden Borre, Dean C Pavlick, Justin M Allen, Christine Parachoniak, Julia Coelho França Quintanilha, Ryon P Graf, Alexa B Schrock, Geoffrey R Oxnard, Christine M Lovly, Hanna Tukachinsky, Vivek Subbiah
Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Timothy Anthony Yap, Naval G Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric-Bernstam, Hagop M Kantarjian, Farhad Ravandi, Meghan E Collins, Maria Emilia Di Francesco, Ecaterina E Dumbrava, Siqing Fu, Sisi Gao, Jason P Gay, Sonal Gera, Jing Han, David S Hong, Elias J Jabbour, Zhenlin Ju, Daniel D Karp, Alessia Lodi, Jennifer R Molina, Natalia Baran, Aung Naing, Maro Ohanian, Shubham Pant, Naveen Pemmaraju, Prithviraj Bose, Sarina A Piha-Paul, Jordi Rodon, Carolina Salguero, Koiji Sasaki, Anand K Singh, Vivek Subbiah, Apostolia M Tsimberidou, Quanyun A Xu, Musa Ylimaz, Qi Zhang, Yuan Li, Christopher A Bristow, Meenakshi B Bhattacharjee, Stefano Tiziani, Timothy P Heffernan, Christopher P Vellano, Philip Jones, Cobi J Heijnen, Annemieke Kavelaars, Joseph R Marszalek, Marina Y Konopleva
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nature medicine 29 (1) (2023)
Kevin A Contrera, Maria K Gule-Monroe, Mimi I Hu, Maria E Cabanillas, Naifa L Busaidy, Ramona Dadu, Steven G Waguespack, Jennifer R Wang, Anastasios Maniakas, Stephen Y Lai, Julia Diersing, Michael Kwon, Elizabeth G Grubbs, Vivek Subbiah, Michelle D Williams, Mark E Zafereo
Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid : official journal of the American Thyroid Association 33 (1) (2023)
Justin T Moyers, Vivek Subbiah
TRKing sarcomas for precision medicine: Seek, and ye shall find! Cancer (2023)
Mohamed A Gouda, Blessie Elizabeth Nelson, Lars Buschhorn, Adam Wahida, Vivek Subbiah
Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical implications. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Blessie Elizabeth Nelson, Jacob J Adashek, Aakash Akshay Sheth, Vivek Subbiah
Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers. Molecular cancer therapeutics 22 (6) (2023)
Vivek Subbiah
The next generation of evidence-based medicine. Nature medicine 29 (1) (2023)
Vivek Subbiah
The next generation of evidence-based medicine. Nature medicine 29 (1) (2023)
Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Curigliano Giuseppe
The emerging role of PI3K inhibitors for solid tumour treatment and beyond. British journal of cancer (2023)
Frank Griesinger, Sreeram Ramagopalan, Winson Y Cheung, Thomas Wilke, Sabrina Mueller, Alind Gupta, Dylan E O'Sullivan, Paul Arora, Darren R Brenner, Carolin Froelich, Jessica Inskip, Ulf Maywald, Vivek Subbiah
Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases. Cancer (2023)
Timothy Anthony Yap, Naval G Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric-Bernstam, Hagop M Kantarjian, Farhad Ravandi, Meghan E Collins, Maria Emilia Di Francesco, Ecaterina E Dumbrava, Siqing Fu, Sisi Gao, Jason P Gay, Sonal Gera, Jing Han, David S Hong, Elias J Jabbour, Zhenlin Ju, Daniel D Karp, Alessia Lodi, Jennifer R Molina, Natalia Baran, Aung Naing, Maro Ohanian, Shubham Pant, Naveen Pemmaraju, Prithviraj Bose, Sarina A Piha-Paul, Jordi Rodon, Carolina Salguero, Koiji Sasaki, Anand K Singh, Vivek Subbiah, Apostolia M Tsimberidou, Quanyun A Xu, Musa Ylimaz, Qi Zhang, Yuan Li, Christopher A Bristow, Meenakshi B Bhattacharjee, Stefano Tiziani, Timothy P Heffernan, Christopher P Vellano, Philip Jones, Cobi J Heijnen, Annemieke Kavelaars, Joseph R Marszalek, Marina Y Konopleva
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nature medicine 29 (1) (2023)
Jie Wu, Vivek Subbiah
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Cancer research 83 (19) (2023)
Aakash Desai, Neha K Reddy, Vivek Subbiah
Top advances of the year: Precision oncology. Cancer (2023)
Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W Hahn, Aung Naing, Shizhen Zhang, Apostolia-Maria Tsimberidou, Jordi Rodon, Siqing Fu, Timothy Anthony Yap, David S Hong, Ming Sun, Yunfang Jiang, Shubham Pant, Amishi Y Shah, Amado J Zurita, Nizar M Tannir, Raghunandan Vikram, Jason Roszik, Funda Meric-Bernstam, Vivek Subbiah
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ precision oncology 7 (1) (2023)
Ryan A Denu, Richard K Yang, Alexander J F Lazar, Shalin S Patel, Valerae O Lewis, Jason Roszik, Jonathan A Livingston, Wei-Lien Wang, Kenna Rael Shaw, Ravin Ratan, Maria Alejandra Zarzour, Justin E Bird, Shaan M Raza, Kadir C Akdemir, Jordi Rodon Ahnert, Vivek Subbiah, Shreyaskumar R Patel, Anthony P Conley
Clinico-genomic profiling of conventional and dedifferentiated chondrosarcomas reveals TP53 mutation to be associated with worse outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Filip Janku, Milind M Javle, Shiraj Sen, Shubham Pant, Lindsay G Bramwell, Vivek Subbiah, Tracey Way, David S Wages, Catherine A Wheeler, Takeaki Suzuki, Kazunori Saeki, Ruth Ann Subach, Timothy Madden, Gary Maier, Mary J Johansen, Kin Cheung, Gerald S Falchook
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. Cancer (2023)
Blessie Elizabeth Nelson, Neha K Reddy, Jason T Huse, Behrang Amini, Mirella Nardo, Mohamed A Gouda, Shiao-Pei Weathers, Vivek Subbiah
Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma. NPJ precision oncology 7 (1) (2023)
Kevin A Contrera, Maria K Gule-Monroe, Mimi I Hu, Maria E Cabanillas, Naifa L Busaidy, Ramona Dadu, Steven G Waguespack, Jennifer R Wang, Anastasios Maniakas, Stephen Y Lai, Julia Diersing, Michael Kwon, Elizabeth G Grubbs, Vivek Subbiah, Michelle D Williams, Mark E Zafereo
Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid : official journal of the American Thyroid Association 33 (1) (2023)
Xiao Zhao, Jennifer Rui Wang, Ramona Dadu, Naifa Lamki Busaidy, Lei Xu, Kim O Learned, Noah N Chasen, Thinh Vu, Anastasios Maniakas, Arturo A Eguia, Julia Diersing, Neil D Gross, Ryan Goepfert, Stephen Y Lai, Marie-Claude Hofmann, Renata Ferrarotto, Charles Lu, Gary Brandon Gunn, Michael T Spiotto, Vivek Subbiah, Michelle D Williams, Maria E Cabanillas, Mark E Zafereo
Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF V600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid : official journal of the American Thyroid Association (2023)
Aakash P Desai, Vivek Subbiah
Direct to patient clinical trials: One small step or a giant leap? Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Gilberto Morgan, Vivek Subbiah
Rare disease research powered by empowered patients: solving the zebra puzzle through social media. Cancer (2023)
Vivek Subbiah
The next generation of evidence-based medicine. Nature medicine 29 (1) (2023)
Deepak Bhamidipati, Sireesha Yedururi, Jason Huse, Sri Veda Chinapuvvula, Jie Wu, Vivek Subbiah
Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer. JCO precision oncology 7 (2023)
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia-Maria Tsimberidou, Maria Cabanillas, Naifa Lamki Busaidy, Milind Javle, Lauren Averett Byers, John Victor Heymach, Funda Meric-Bernstam, Vivek Subbiah
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ precision oncology 7 (1) (2023)
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia-Maria Tsimberidou, Maria Cabanillas, Naifa Lamki Busaidy, Milind Javle, Lauren Averett Byers, John Victor Heymach, Funda Meric-Bernstam, Vivek Subbiah
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ precision oncology 7 (1) (2023)
Mohamed A Gouda, Vivek Subbiah
Precision oncology with selective RET inhibitor selpercatinib in RET -rearranged cancers. Therapeutic advances in medical oncology 15 (2023)
Mohamed A Gouda, Vivek Subbiah
Precision oncology with selective RET inhibitor selpercatinib in RET -rearranged cancers. Therapeutic advances in medical oncology 15 (2023)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer research communications (2023)
Vivek Subbiah
The next generation of evidence-based medicine. Nature medicine 29 (1) (2023)
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Anas Gazzah, Ulrik N Lassen, Alexander Stein, Patrick Y Wen, Sascha Dietrich, Maja J A de Jonge, Jean Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C Cho, Filip Yves Francine De Vos, Philippe Moreau, Elena Elez Fernandez, Jan H M Schellens, Christoph C Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nature medicine (2023)
Kevin A Contrera, Maria K Gule-Monroe, Mimi I Hu, Maria E Cabanillas, Naifa L Busaidy, Ramona Dadu, Steven G Waguespack, Jennifer R Wang, Anastasios Maniakas, Stephen Y Lai, Julia Diersing, Michael Kwon, Elizabeth G Grubbs, Vivek Subbiah, Michelle D Williams, Mark E Zafereo
Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid : official journal of the American Thyroid Association 33 (1) (2023)
Giannis S Mountzios, Jordi Remon, Lizza E L Hendriks, Rosario García-Campelo, Christian C Rolfo, Paul Van Schil, Patrick M Forde, Benjamin Besse, Vivek Subbiah, Martin Reck, Jean-Charles Soria, Solange Peters
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nature reviews. Clinical oncology (2023)
Timothy Anthony Yap, Naval G Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric-Bernstam, Hagop M Kantarjian, Farhad Ravandi, Meghan E Collins, Maria Emilia Di Francesco, Ecaterina E Dumbrava, Siqing Fu, Sisi Gao, Jason P Gay, Sonal Gera, Jing Han, David S Hong, Elias J Jabbour, Zhenlin Ju, Daniel D Karp, Alessia Lodi, Jennifer R Molina, Natalia Baran, Aung Naing, Maro Ohanian, Shubham Pant, Naveen Pemmaraju, Prithviraj Bose, Sarina A Piha-Paul, Jordi Rodon, Carolina Salguero, Koiji Sasaki, Anand K Singh, Vivek Subbiah, Apostolia M Tsimberidou, Quanyun A Xu, Musa Ylimaz, Qi Zhang, Yuan Li, Christopher A Bristow, Meenakshi B Bhattacharjee, Stefano Tiziani, Timothy P Heffernan, Christopher P Vellano, Philip Jones, Cobi J Heijnen, Annemieke Kavelaars, Joseph R Marszalek, Marina Y Konopleva
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nature medicine (2023)
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia-Maria Tsimberidou, Maria Cabanillas, Naifa Lamki Busaidy, Milind Javle, Lauren Averett Byers, John Victor Heymach, Funda Meric-Bernstam, Vivek Subbiah
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ precision oncology 7 (1) (2023)
Mohamed A Gouda, Vivek Subbiah
Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 43 (2023)
Vivek Subbiah, Philippe A Cassier, Salvatore Siena, Elena Garralda, Luis Paz-Ares, Pilar Garrido Lopez, Ernest Nadal, Jacqueline Vuky, Gilberto Lopes, Gregory P Kalemkerian, Daniel W Bowles, Mahesh Seetharam, Jianhua Chang, Hui Zhang, Jennifer Green, Alena Zalutskaya, Martin Schuler, Yun Fan, Curigliano Giuseppe
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nature medicine 28 (8) (2022)
Jacob J Adashek, Arjun K Menta, Neha K Reddy, Aakash P Desai, Jason Roszik, Vivek Subbiah
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. Molecular cancer therapeutics 21 (6) (2022)
Christian Caglevic, Christian D Rolfo, Ignacio Gil-Bazo, Andrés Felipe Cardona, Jorge Sapunar, Fred R Hirsch, David R Gandara, Gilberto Morgan, Silvia Novello, Marina-Chiara Garassino, Giannis S Mountzios, Natasha B Leighl, Denisse Bretel, Arrieta Oscar, Alfredo Addeo, Stephen V Liu, Luis Corrales-Rodríguez, Vivek Subbiah, Francisco Aboitiz, Franz Villaroel-Espindola, Felipe Reyes-Cosmelli, Ricardo Morales, Mauricio Mahave, Luis Raez, Jorge Alatorre, Edgardo S Santos, Luis Ubillos, Daniel Shao-Weng Tan, Christoph C Zielinski
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations. JCO global oncology 8 (2022)
Hani M Babiker, Erkut Hasan Borazanci, Vivek Subbiah, Sanjiv Agarwala, Alain Patrick Algazi, Jacob Schachter, Michael Lotem, Corinne Maurice-Dror, Daniel Hendler, Shah Rahimian, Hans Minderman, Cara L Haymaker, Daruka Mahadevan, Chantale Bernatchez, Ravi Murthy, Rolf Hultsch, Nadia Kaplan, Gregory Woodhead, Charles Hennemeyer, Srinivas Chunduru, Peter M Anderson, Adi Diab, Igor Puzanov
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clinical cancer research : an official journal of the American Association for Cancer Research 28 (23) (2022)
Vivek Subbiah, Boyi Gan
Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1? Clinical cancer research : an official journal of the American Association for Cancer Research 28 (16) (2022)
Justin Tyler Moyers, Roberto Carmagnani Pestana, Jason Roszik, David S Hong, Aung Naing, Siqing Fu, Sarina A Piha-Paul, Timothy Anthony Yap, Daniel D Karp, Jordi Rodon Ahnert, Jonathan A Livingston, Maria Alejandra Zarzour, Vinod Ravi, Shreyaskumar R Patel, Robert S Benjamin, Joseph A Ludwig, Cynthia E Herzog, Ravin Ratan, Neeta Somaiah, Anthony P Conley, Richard G Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Aakash Desai, Vivek Subbiah
Rationalizing rules for immunotherapy combination trials: About time for precision immunotherapy. Cancer (2022)
Mohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, S Greg Call, Daniel D Karp, Siqing Fu, Aung Naing, Vivek Subbiah, Shubham Pant, Derek J Dustin, Apostolia-Maria Tsimberidou, David S Hong, Jordi Rodon Ahnert, Funda Meric-Bernstam, Filip Janku
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO precision oncology 6 (2022)
Michael J Wagner, Cassandra Hennessy, Alicia Beeghly, Benjamin French, Dimpy P Shah, Sarah Croessmann, Diana Vilar Compte, Erika Ruiz-Garcia, Matthew Ingham, Gary K Schwartz, Corrie A Painter, Rashmi Chugh, Leslie Fecher, Cathleen Park, Olga Zamulko, Jonathan C Trent, Vivek Subbiah, Ali Raza Khaki, Lisa Tachiki, Elizabeth S Nakasone, Elizabeth T Loggers, Chris Labaki, Renee Maria Saliby, Rana R McKay, Archana Ajmera, Elizabeth A Griffiths, Igor Puzanov, William D Tap, Clara Hwang, Sheela Tejwani, Sachin M Jhawar, Brandon Hayes-Lattin, Elizabeth Marie Wulff-Burchfield, Anup Kasi, Daniel Y Reuben, Gayathri Nagaraj, Monika D Joshi, Hyma Polimera, Amit A Kulkarni, Khashayar Esfahani, Daniel H Kwon, Luca Paoluzzi, Mehmet A Bilen, Eric B Durbin, Petros D Grivas, Jeremy L Warner, Elizabeth J Davis, null null
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study. Cancers 14 (17) (2022)
Justin Tyler Moyers, Vivek Subbiah
Think Globally, Act Locally: Globalizing Precision Oncology. Cancer discovery 12 (4) (2022)
Tito R Mendoza, David S Hong, Christine B Peterson, Bettzy Stephen, Ecaterina Dumbrava, Shubbam Pant, Apostolia Maria Tsimberidou, Timothy Anthony Yap, Ajay Sheshadri, Mehmet Altan, Goldy George, Lilibeth Castillo, Enedelia Rodriguez, Jing Gong, Vivek Subbiah, Filip Janku, Siqing Fu, Sarina A Piha-Paul, Jordi Rodon Ahnert, Daniel D Karp, Charles Cleeland, Funda Meric-Bernstam, Aung Naing
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Scientific reports 12 (1) (2022)
Alexander E Drilon, Vivek Subbiah, Oliver Gautschi, Pascale Tomasini, Filippo de Braud, Benjamin J Solomon, Daniel Shao-Weng Tan, Guzmán Alonso, Juergen Wolf, Keunchil Park, Koichi Goto, Victoria Soldatenkova, Sylwia Szymczak, Scott S Barker, Tarun Puri, Aimee Bence Lin, Herbert Ho-Fung Loong, Benjamin Besse
Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Robert J Kreitman, Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne-Sophie Michallet, Zev A Wainberg, Alexander Stein, Sascha Dietrich, Maja J A de Jonge, Wolfgang Willenbacher, Jacques De Grève, Evgeny Arons, Palanichamy Ilankumaran, Paul Burgess, Eduard Gasal, Vivek Subbiah
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood (2022)
Sanjay Popat, Stephen V Liu, Nicolas Scheuer, Grace G Hsu, Alexandre Lockhart, Sreeram V Ramagopalan, Frank Griesinger, Vivek Subbiah
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. Nature communications 13 (1) (2022)
Blessie Elizabeth Nelson, Jacob J Adashek, Steven H Lin, Vivek Subbiah
On target methods to induce abscopal phenomenon for Off-Target effects: From happenstance to happenings. Cancer medicine (2022)
Matteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, Shunji Takahashi, John Sarantopoulos, Andrea Varga, Joseph A D'Alessio, Tinya Abrams, Qing Sheng, Eugene Youchin Tan, Maria Santos Rosa, Juan Gonzalez-Maffe, Janna Sand-Dejmek, Claire Fabre, Miguel Martin
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors. Molecular cancer therapeutics 21 (4) (2022)
Stephen Capone, Leena M Ketonen, Shiao-Pei Weathers, Vivek Subbiah
Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1 N546K Mutation. JCO precision oncology 6 (2022)
Issam Raad, Ray Hachem, Nigo Masayuki, Tarcila Datoguia, Hiba Dagher, Ying Jiang, Vivek Subbiah, Bilal Siddiqui, Arnaud Bayle, Robert Somer, Ana Fernández Cruz, Edward Gorak, Arvinder Bhinder, Nobuyoshi Mori, Nelson Hamerschlak, Samuel Shelanski, Tomislav Dragivich, Yee Elise Vong Kiat, Suha Fakhreddine, Pierre Abi Hanna, Roy F Chemaly, Victor Mulanovich, Javier Adachi, Jovan Borjan, Fareed Khawaja, Bruno Granwehr, Teny John, Eduardo Yepez Guevara, Harrys Torres, Natraj Reddy Ammakkanavar, Marcel Yibirin, Cielito C Reyes-Gibby, Mala Pande, Noman Ali, Raniv Dawey Rojo, Shahnoor M Ali, Rita E Deeba, Patrick Chaftari, Takahiro Matsuo, Kazuhiro Ishikawa, Ryo Hasegawa, Ramón Aguado-Noya, Álvaro García-García, Cristina Traseira Puchol, Dong-Gun Lee, Monica Slavin, Benjamin W Teh, Cesar A Arias, null null, Dimitrios P Kontoyiannis, Alexandre E Malek, Anne-Marie Chaftari
International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship. medRxiv : the preprint server for health sciences (2022)
Vivek Subbiah, Irene Brana, Alessandra Longhi, Valentina Boni, Jean-Pierre Delord, Ahmad Awada, Pascaline Boudou-Rouquette, John Sarantopoulos, Geoffrey I Shapiro, Anthony D Elias, Ravin Ratan, Cristian Fernandez, Carmen Kahatt, Martin Cullell-Young, Mariano Siguero, Ali Zeaiter, Sant P Chawla
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (13) (2022)
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A Nebhan, Ibiayi Dagogo-Jack, Nathaniel J Myall, Georg Richtig, Jillian Wilhelmina Paulina Bracht, Marco Gerlinger, Eiji Shinozaki, Takayuki Yoshino, Daisuke Kotani, Jason R Fangusaro, Oliver Gautschi, Julien Mazieres, Jeffrey A Sosman, Edmund S Kopetz, Vivek Subbiah, Michael A Davies, Anna L Groover, Ryan J Sullivan, Keith T Flaherty, Douglas B Johnson, Andrea Benedetti, David W Cescon, Anna Spreafico, George Zogopoulos, April A N Rose
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. JCO precision oncology 6 (2022)

Vivek Subbiah.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Vivek Subbiah